STOCK TITAN
  1. Home
  2. Financials
  3. CDT

CDT Equity Financials

CDT
Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows CDT Equity (CDT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CDT FY2025

External financing is carrying the business as cash burn outruns liquidity and pushes the balance sheet deeper into negative equity.

From FY2023 to FY2025, operating cash burn roughly doubled from -$7.7M to -$15.6M, yet year-end cash was only $1.5M because financing inflows of $17.4M mostly replaced cash consumed by operations rather than building liquidity. The core pattern is funding dependence: new capital is keeping the business moving, but not yet creating a larger cash buffer.

Book capital deteriorated sharply: equity moved from -$457K in FY2023 to -$7.2M in FY2025 while liabilities reached $12.8M against $5.7M of assets, showing that losses have consumed more than the asset base can offset.

Near-term liquidity also tightened, with the current ratio falling from 3.2x in FY2023 to 0.3x in FY2025. Even though cash rose from FY2024's $554K to $1.5M, short-term obligations expanded faster, so the financing need is not just long-term but immediate.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score pending refresh

We are recalculating CDT Equity's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
N/A
Net Income
N/A
EPS (Diluted)
$-1177.89

CDT Equity earned $-1177.89 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$1.5M
YoY+172.4%

CDT Equity held $1.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
92,140

CDT Equity had 92,140 shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
$5.1M
YoY+49.6%

CDT Equity invested $5.1M in research and development in fiscal year 2025. This represents an increase of 49.6% from the prior year.

Share Buybacks
$106K

CDT Equity spent $106K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures
N/A

CDT Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses $778K N/A $1.5M-17.6% $1.9M+103.1% $916K N/A $3.1M+12272.0% $25K
SG&A Expenses $2.9M N/A $5.5M+77.9% $3.1M+14.5% $2.7M N/A $2.7M-12.7% $3.1M
Operating Income -$3.7M N/A -$7.0M-42.0% -$5.0M-36.9% -$3.6M N/A -$5.8M-85.1% -$3.1M
Interest Expense N/A N/A $100K0.0% $100K0.0% $100K N/A $49K+22.5% $40K
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income -$4.1M N/A -$7.1M-18.1% -$6.0M-26.8% -$4.8M N/A -$6.5M-20.0% -$5.4M
EPS (Diluted) $-5.56 N/A $-13.16-141.0% $-5.46+99.9% $-3670.27 N/A $-889.58-713.7% $-109.33

CDT Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $127.1M+2149.3% $5.7M-33.9% $8.6M+7.0% $8.0M+3.6% $7.7M+84.0% $4.2M+40.1% $3.0M-9.4% $3.3M
Current Assets $3.1M-30.3% $4.4M-38.3% $7.1M+11.1% $6.4M+7.3% $5.9M+119.1% $2.7M+94.3% $1.4M-12.7% $1.6M
Cash & Equivalents $97K-93.6% $1.5M-60.7% $3.8M+15.2% $3.3M+56.4% $2.1M+284.5% $554K+680.3% $71K-67.6% $219K
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $21.6M+68.8% $12.8M+200.0% $4.3M-4.2% $4.5M-3.8% $4.6M-57.8% $11.0M-9.3% $12.1M+38.1% $8.8M
Current Liabilities $21.6M+68.8% $12.8M+200.6% $4.3M-3.4% $4.4M-3.0% $4.5M-57.7% $10.7M-10.3% $12.0M+39.4% $8.6M
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity $105.5M+1570.7% -$7.2M-267.6% $4.3M+21.2% $3.5M+14.6% $3.1M+145.3% -$6.8M+25.5% -$9.1M-66.9% -$5.5M
Retained Earnings -$72.4M-5.9% -$68.3M-45.4% -$47.0M-17.8% -$39.9M-17.8% -$33.9M-16.3% -$29.1M-9.0% -$26.7M-31.9% -$20.2M

CDT Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow -$1.9M+59.1% -$4.6M-5.1% -$4.4M-70.9% -$2.6M+34.3% -$3.9M-3.0% -$3.8M-90.7% -$2.0M-32.1% -$1.5M
Capital Expenditures N/A N/A -$7K-800.0% $1K-99.8% $404K $0-100.0% $41K N/A
Free Cash Flow N/A N/A -$4.4M-71.1% -$2.6M+40.4% -$4.3M-13.6% -$3.8M-86.9% -$2.0M N/A
Investing Cash Flow N/A $595K+159.6% -$998K-99700.0% -$1K+99.8% -$404K-575.3% $85K-11.5% $96K N/A
Financing Cash Flow $487K-72.0% $1.7M-71.0% $6.0M+59.6% $3.8M-36.6% $5.9M+40.8% $4.2M+141.4% $1.7M N/A
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

CDT Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity -3.9% N/A -166.4%+4.4pp -170.8%-16.5pp -154.3% N/A N/A N/A
Return on Assets -3.2% N/A -83.2%-7.8pp -75.4%-13.8pp -61.6% N/A -215.9%-53.0pp -162.9%
Current Ratio 0.14-0.2 0.34-1.3 1.66+0.2 1.45+0.1 1.31+1.1 0.25+0.1 0.12-0.1 0.19
Debt-to-Equity 0.21+2.0 -1.79-2.8 1.00-0.3 1.26-0.2 1.50+3.1 -1.62-0.3 -1.33+0.3 -1.61
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$7.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.34), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Windtree Therapeutics Inc WINT
$13.8M
Purple Biotech Ltd PPBT
$1.3M
Scinai Immunotherapeutics Ltd. SCNI
$1.3M
Psyence Biomedical Ltd. PBM
$10.8M
Lipella Pharmaceuticals Inc LIPO
$11.8M

Frequently Asked Questions

CDT Equity (CDT) reported diluted earnings per share of $-1177.89 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CDT Equity (CDT) generated -$15.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

CDT Equity (CDT) had $5.7M in total assets as of fiscal year 2025, including both current and long-term assets.

CDT Equity (CDT) invested $5.1M in research and development during fiscal year 2025.

Yes, CDT Equity (CDT) spent $106K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

CDT Equity (CDT) had 92,140 shares outstanding as of fiscal year 2025.

CDT Equity (CDT) had a current ratio of 0.34 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

CDT Equity (CDT) had a debt-to-equity ratio of -1.79 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Based on fiscal year 2025 data, CDT Equity (CDT) had $1.5M in cash against an annual operating cash burn of $15.6M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

CDT Equity (CDT) has negative shareholder equity of -$7.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Back to top